• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Ricerca

    Tutto UVaDOCArchiviData di pubblicazioneAutoriSoggettiTitoli

    My Account

    Login

    Estadísticas

    Ver Estadísticas de uso

    Compartir

    Mostra Item 
    •   UVaDOC Home
    • PRODUZIONE SCIENTIFICA
    • Departamentos
    • Untitled
    • DEP05 - Artículos de revista
    • Mostra Item
    •   UVaDOC Home
    • PRODUZIONE SCIENTIFICA
    • Departamentos
    • Untitled
    • DEP05 - Artículos de revista
    • Mostra Item
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/63443

    Título
    Impact of innovative treatment using biological drugs for the modulation of diffuse cutaneous systemic sclerosis: A systematic review
    Autor
    Fernández Lázaro, DiegoAutoridad UVA
    Iglesias Lázaro, María
    Garrosa, Evelina
    Rodríguez García, Saray
    Jerves Donoso, David
    Gutiérrez Abejón, EduardoAutoridad UVA Orcid
    Jorge Finnigan, ConradoAutoridad UVA Orcid
    Año del Documento
    2023
    Descripción
    Producción Científica
    Documento Fuente
    Medicina, 2023, Vol. 59, Nº. 2, 247
    Abstract
    Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment available, so therapeutic action is aimed at a symptomatic treatment of the affected organs. The development of biotechnology has made it possible to implement certain biological drugs that could represent a window of opportunity to modulate the evolution and symptomatology of scleroderma with greater efficacy and less toxicity than conventional treatments. This study aimed to review the current evidence critically and systematically on the effects of biological drugs on the pulmonary function, skin disease, and health status of patients afflicted by diffuse cutaneous systemic sclerosis (dcSSc). Three electronic databases (Pubmed, Dialnet, and Cochrane Library Plus) were systematically searched until the cut-off date of October 2022. The review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included original articles in English and Spanish with a controlled trial design, comparing biological drug treatments (tocilizumab, belimumab, riociguat, abatacept, and romilkimab) with a control group. The methodological quality of the studies was assessed using the McMaster quantitative form and the PEDro scale. A total of 383 studies were identified, 6 of them met the established criteria and were included in the present systematic review. A total of 426 patients treated with tocilizumab, belimumab, riociguat, abatacept, and romilkimab were included. The results showed substantial non-significant (p < 0.05) improvement trends after treatment with the biological drugs included in this review for the modified Rodnan Scale Value, Forced Vital Capacity, and Carbon Monoxide Diffusion Test; however, no benefits were shown on the Health Assessment Questionnaire–Disability Index when compared to the control group. Biological drugs, therefore, maybe a new therapeutic strategy for dcSSc and could be recommended as an additional and/or adjunctive treatment that promotes anti-fibrotic activity. This review could further define the clinical rationale for the use of biologics in the treatment of dcSSc and could provide key details on the study protocol, design, and outcome reporting.
    Materias (normalizadas)
    Scleroderma (Disease)
    Esclerodermia (Enfermedad)
    Autoimmune diseases
    Enfermedades autoinmunes
    Skin - Diseases
    Piel - Enfermedades
    Systemic scleroderma
    Immunology
    Dermatology
    Rheumatology
    Respiratory organs - Diseases
    Pulmonary function tests
    Lungs - Diseases
    Organos respiratorios - Enfermedades
    Pulmones - Enfermedades
    Health status indicators
    Biological products - Therapeutic use
    Drugs - Therapeutic use
    Medicamentos - Uso
    Public health
    Materias Unesco
    2412 Inmunología
    3201.06 Dermatología
    3205.09 Reumatología
    3205.08 Enfermedades Pulmonares
    3212 Salud Publica
    ISSN
    1648-9144
    Revisión por pares
    SI
    DOI
    10.3390/medicina59020247
    Patrocinador
    Caja Rural de Soria - (project SO-12-2022)
    Version del Editor
    https://www.mdpi.com/1648-9144/59/2/247
    Propietario de los Derechos
    © 2023 The authors
    Idioma
    eng
    URI
    https://uvadoc.uva.es/handle/10324/63443
    Tipo de versión
    info:eu-repo/semantics/publishedVersion
    Derechos
    openAccess
    Aparece en las colecciones
    • DEP05 - Artículos de revista [198]
    Mostra tutti i dati dell'item
    Files in questo item
    Nombre:
    Impact-of-Innovative-Treatment-Using-Biological-Drugs.pdf
    Tamaño:
    669.8Kb
    Formato:
    Adobe PDF
    Thumbnail
    Mostra/Apri
    Atribución 4.0 InternacionalLa licencia del ítem se describe como Atribución 4.0 Internacional

    Ítems relacionados

    Mostrando ítems relacionados por Título, autor o materia.

    • Thumbnail

      Combination of BeGraft and Solaris stent grafts for the covered endovascular reconstruction of aortic bifurcation—BS-CERAB technique 

      San Norberto García, Enrique MaríaAutoridad UVA; Revilla, Álvaro; Brizuela Sanz, José AntonioAutoridad UVA; Blanco Alonso, María Isabel DelAutoridad UVA; Flores, Ángel; Taylor, James (2024)
    • Thumbnail

      Flare-ups in Crohn’s disease: Influence of stress and the external locus of control 

      De Dios Duarte, María JoséAutoridad UVA; Arias Astray, Andrés; Durántez Fernández, CarlosAutoridad UVA; Niño Martín, VirtudesAutoridad UVA; Olea Fraile, ElenaAutoridad UVA; Barba Pérez, María ÁngelesAutoridad UVA; Pérez Pérez, LucíaAutoridad UVA; Cardaba García, Rosa MaríaAutoridad UVA; Barrón, Ana (2022)
    • Thumbnail

      Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies. A real-life cohort study 

      Maza Solano, Juan; Calvo Henríquez, Christian; Alobid, Isam; Álvarez Cendrero, Marta; Palomares, Óscar; Moreno Luna, Ramón; Santos Pérez, JaimeAutoridad UVA; González García, Jaime; Sánchez Gómez, Serafín (2022)

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10